MKI67 and gastrointestinal stromal tumor: Particularly, in the high-risk GIST group the rate of recurrence was higher in patients with a Ki67 index >8% (11), suggesting that the Ki67 index >8% was an unfavorable factor for adjuvant imatinib therapy (12, 13).